This study aimed to enhance the solubility of a poorly water-soluble drug, pranlukast, as well as its transport across Madin-Darby canine kidney (MDCK) monolayers, thus increasing its oral bioavailability. To accomplish this aim, we prepared a pranlukast-phospholipid complex (PPC). The PPC was prepared by solvent-evaporation and characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), infrared (IR) spectroscopy, and solubilization studies. The solubility of pranlukast in the PPC was increased from 1.03 ± 0.32 μg/ml to 160.63 ± 2.72 μg/ml with a yield of 96.39 ± 1.20% when the PPC was prepared under optimal conditions. TEM images showed that the PPC particles had a spherical shape. XRD data indicated that pranlukast in the PPC was either in an amorphous form or in a dispersed molecular distribution. IR analysis confirmed the interaction between pranlukast and the phospholipids. The transport mechanism of the PPC and non-complexed pranlukast across MDCK cells was measured and was observed to be significantly greater for the former than for the latter. The in vivo bioavailability of the PPC in rats hastened the onset of pranlukast-induced therapeutic effects, with Cmax and AUC increases of 21.88- and 28.64-fold, respectively, compared with raw crystals. In addition, an in vivo imaging method was used to corroborate that the PPC exhibited rapid circulatory distribution and gastrointestinal tract accumulation. These results indicate that PPC appears to be a promising drug delivery system for pranlukast, improving drug absorption and decreasing side effects by reducing the required oral dose.
Inhibition of protein disulfide isomerase (PDI) has been attempted as a promising anti-cancer strategy. However, there is still no currently available PDI inhibitors approved for clinical use. Here, we isolated seven high yield alkaloids from Stephaniae tetrandrae Radix (STR), a medical herb frequently prescribed in anti-tumor condition, and identified two potent natural PDI inhibitors, dicentrine and dicentrinone. Among the seven alkaloids isolated, dicentrinone (1), dicentrine (2), tetrandrine (4), and fangchinoline (5) could significantly reduce cell viability in a dosage dependent manner detected by MTT assay in human hepatoma cells. To examine whether the candidate compounds are potent PDI inhibitors, we performed insulin turbidity assay and found dicentrine and dicentrinone, but not tetrandrine and fangchinoline, could effectively inhibit PDI activity, with IC50 of 56.70 μM and 43.95 μM respectively. Meanwhile, dicentrine and dicentrinone failed to further reduce the cell number index when co-treated with siRNA of PDI, suggesting the compounds behave as PDI inhibitors. Furthermore, dicentrinone and dicentrine have been successfully docked to the active pocket of PDI (PDB #3UEM) by molecular docking, suggesting the existence of physical interaction between compounds and PDI. Our results suggested that dicentrine and dicentrinone may be developed into safe PDI inhibitors.
9 March 2026 in International Journal of Pharmacology
Medicinal plants have long been used to manage hyperuricemia (HUA) and gout, with flavonoids identified as key bioactive components. However, the therapeutic effects of flavonoids on HUA remain inadequately characterized. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of flavonoids on serum uric acid (UA) and xanthine oxidase (XOD) activity in animal models. A comprehensive literature search of the PubMed and Web of Science databases (January 2007–December 2024) identified 21 eligible studies involving 550 male mice. A random-effects meta-analysis revealed that flavonoid administration significantly reduced serum UA (standardized mean difference [SMD] = –2.22, 95% confidence interval (CI): –2.80 to –1.64; p < 0.001) and XOD activity (SMD = –1.79, 95% CI: –2.50 to –1.08; p < 0.001). Subgroup analyses indicated that chalcones, flavonols, and flavones exerted the most pronounced hypouricemic effects. Molecular docking of 28 flavonoids to XOD yielded binding affinities ranging from –8.4 to –10.9 kcal/mol, with molecular dynamics simulations confirming stable ligand–enzyme complexes; flavones exhibited the highest stability. Collectively, these data provide robust preclinical evidence that flavonoids ameliorate hyperuricemia via dual mechanisms of UA reduction and XOD inhibition, and support the further clinical development of flavonoids as potential natural agents for managing HUA.
15 March 2025 in International Journal of Pharmacology